Immunotherapy by allogeneic stem cell transplantation.

[1]  G. Gahrton,et al.  Successful treatment with prednisone and graft-versus-host disease in an allogeneic bone-marrow transplant recipient. , 2009, Scandinavian journal of haematology.

[2]  P. Pedrazzoli,et al.  Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[4]  S. Rosenberg,et al.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells , 2005, The Journal of experimental medicine.

[5]  M. Remberger,et al.  Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[6]  A. Barrett,et al.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.

[7]  A. Ballestrero,et al.  Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer , 2005, The Lancet.

[8]  M. Horowitz,et al.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. , 2005, Blood.

[9]  O. Ringdén,et al.  Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  M. Remberger,et al.  Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. , 2005, Experimental hematology.

[12]  O. Ringdén,et al.  Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. , 2005, Experimental cell research.

[13]  K. Ohtomo,et al.  Graft-versus-Tumor Effect Against Advanced Pancreatic Cancer after Allogeneic Reduced-Intensity Stem Cell Transplantation , 2005, Transplantation.

[14]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[15]  B. Blazar,et al.  Regulatory T cells. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  J. Ferrara,et al.  Graft vs. Host Disease, Third Edition , 2004 .

[17]  L. Cheng,et al.  Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. , 2004, Transplantation proceedings.

[18]  J. G. van den Tweel,et al.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. , 2004, Blood.

[19]  H. Ljunggren,et al.  Increased Infection-Related Mortality in KIR-Ligand–Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation , 2004, Transplantation.

[20]  S. Steinberg,et al.  Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit the Expression of CD25 (Interleukin‐2 Receptor) and CD38 on Phytohaemagglutinin‐Activated Lymphocytes , 2004, Scandinavian journal of immunology.

[22]  M. Remberger,et al.  Indium–111-Labelled Donor-Lymphocyte Infusion by way of Hepatic Artery and Radio-Frequency Ablation against Liver Metastases of Renal and Colon Carcinoma after Allogeneic Hematopoietic Stem-Cell Transplantation , 2004, Transplantation.

[23]  J. P. McCoy,et al.  Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. , 2004, Blood.

[24]  G. Dellgren,et al.  Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. , 2004, The Journal of thoracic and cardiovascular surgery.

[25]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[26]  G. Ehninger,et al.  Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. , 2004, Blood.

[27]  H. Sakamaki,et al.  Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Unresectable Pancreatic Cancer , 2004, Pancreas.

[28]  S. Haynesworth,et al.  Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation , 2004, Bone Marrow Transplantation.

[29]  P. Ljungman,et al.  Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  M. Labopin,et al.  Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Blaise,et al.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. , 2004, Blood.

[32]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[33]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[34]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[35]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[36]  Franco Locatelli,et al.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. , 2003, Blood.

[37]  M. Remberger,et al.  G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II–IV , 2003, Bone Marrow Transplantation.

[38]  R. Gale,et al.  Decreased treatment failure in recipients of HLA‐identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses , 2003, British journal of haematology.

[39]  H. Sakamaki,et al.  Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation , 2003, Bone Marrow Transplantation.

[40]  O. Ringdén,et al.  Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans1 , 2003, Transplantation.

[41]  C. Cobbs,et al.  Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. , 2003, Blood.

[42]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[43]  P. Pisa,et al.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma , 2003, Bone Marrow Transplantation.

[44]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[45]  M. Labopin,et al.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Spivak,et al.  Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.

[47]  M. Remberger,et al.  Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. , 2002, Blood.

[48]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[49]  Todd A Fehniger,et al.  Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. , 2002, Blood.

[50]  N. Schmitz,et al.  Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. , 2002, Blood.

[51]  V. Levitsky,et al.  Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion. , 2002, Journal of hematotherapy & stem cell research.

[52]  D. Blaise,et al.  Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients , 2002, Bone Marrow Transplantation.

[53]  C. Voena,et al.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.

[54]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[55]  P. Pedrazzoli,et al.  Allogeneic blood stem cell transplantation after a reduced‐intensity, preparative regimen , 2002, Cancer.

[56]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[57]  H. Deeg,et al.  SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 , 2001, Transplantation.

[58]  O. Ringdén,et al.  Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation , 2001, Leukemia.

[59]  O. Ringdén,et al.  A graft-versus-colonic cancer effect of allogeneic stem cell transplantation , 2001, Bone Marrow Transplantation.

[60]  N. Fisk,et al.  Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. , 2001, Blood.

[61]  H. Deeg,et al.  Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. , 2001, Blood.

[62]  M. Remberger,et al.  The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. , 2001, Blood.

[63]  G. Kobbe,et al.  Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody , 2001, Bone Marrow Transplantation.

[64]  M. Remberger,et al.  Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.

[65]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[66]  T. Zimmerman,et al.  Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. , 2001, The Journal of urology.

[67]  V. Levitsky,et al.  Poor immune reconstitution after four or five major HLA antigens mismatched T cell‐depleted allogeneic and autologous stem cell transplantation , 2001, Clinical and experimental immunology.

[68]  N. Schmitz,et al.  Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? , 2000 .

[69]  C. Craddock,et al.  Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2000, Blood.

[70]  J. Armitage,et al.  Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Gratwohl,et al.  Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. , 2000, Blood.

[72]  M. Remberger,et al.  Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. , 2000, Transplantation.

[73]  C. Mullen,et al.  Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. , 2000, Blood.

[74]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[75]  E. Kimby,et al.  Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease , 2000, Leukemia.

[76]  O. Ringdén,et al.  Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia , 2000, Bone Marrow Transplantation.

[77]  N. Chao,et al.  Pathophysiologic mechanisms of acute graft-vs.-host disease. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[78]  M. Remberger,et al.  Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia , 1999, Bone Marrow Transplantation.

[79]  R. Storb,et al.  Mixed chimerism: preclinical studies and clinical applications. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[80]  N. Hensel,et al.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  F. Révillion,et al.  Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay , 1999, Leukemia.

[82]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[83]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[84]  J. Hancock,et al.  Minimal Residual Disease Status Before Allogeneic Bone Marrow Transplantation Is an Important Determinant of Successful Outcome for Children and Adolescents With Acute Lymphoblastic Leukemia , 1998 .

[85]  M. Gavin,et al.  Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. , 1998, Current opinion in hematology.

[86]  P. Ljungman,et al.  Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis , 1998, Bone Marrow Transplantation.

[87]  J. Hancock,et al.  Minimal residula disease status as a predictor of relapse after allogenic bone marrow transplantation for children with acute lymphoblastic leukaemia , 1998, British journal of haematology.

[88]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[89]  E. Warren,et al.  Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.

[90]  H. Einsele,et al.  Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT , 1998, Bone Marrow Transplantation.

[91]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[93]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[94]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[95]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[96]  E. Goulmy.  Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy , 1997, Immunological reviews.

[97]  Y. Moshel,et al.  Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma , 1997, International journal of cancer.

[98]  R. Hoover,et al.  Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.

[99]  F. Preijers,et al.  Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. , 1997, Journal of immunology.

[100]  M. Labopin,et al.  The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Leukemia & lymphoma.

[101]  A. Nagler,et al.  Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia , 1996, The Lancet.

[102]  J. Fay,et al.  FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.

[103]  M. Labopin,et al.  Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[104]  P. McCarthy,et al.  A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. , 1996, Transplantation.

[105]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.

[106]  M. Bonneville,et al.  Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host- graft-versus-leukemia reaction? , 1996, Blood.

[107]  J. Wagner,et al.  Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. , 1996, Blood.

[108]  J. Goldman,et al.  Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. , 1996, Blood.

[109]  I. Pastan,et al.  Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.

[110]  K. Akashi,et al.  Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. , 1996, Bone marrow transplantation.

[111]  J. Armitage,et al.  Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[113]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[114]  G. Socié,et al.  Studies on hemopoietic chimerism following allogeneic bone marrow transplantation in the molecular biology era. , 1995, Leukemia research.

[115]  Charles E. Kahn,et al.  graft-vs.-host disease , 1995 .

[116]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[117]  T. Waldmann,et al.  Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. , 1994, Blood.

[118]  Craig W. Reynolds,et al.  Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? , 1994, Blood.

[119]  L. Barnett,et al.  Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. , 1994, Blood.

[120]  J. Wijnen,et al.  Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. , 1994, Blood.

[121]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[122]  A. Tichelli,et al.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.

[123]  A. Chase,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993, Blood.

[124]  J. V. van Dongen,et al.  Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. , 1993, Leukemia.

[125]  A A Rimm,et al.  Outcome after allogeneic bone marrow transplant for leukemia in older adults. , 1993, JAMA.

[126]  P. Ljungman,et al.  Increased risk of relapse in patients with chronic myelogenous leukemia given T‐cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft‐versus‐host disease , 1993, European journal of haematology.

[127]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.

[128]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[129]  J. Bourhis,et al.  Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. , 1992, Blood.

[130]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[131]  D. Blaise,et al.  Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. , 1991, Blood.

[132]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[133]  Arnold I. Caplan,et al.  Mesenchymal Stem Cells , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[134]  P. Humphries,et al.  Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction , 1991 .

[135]  F. Frassoni,et al.  Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. , 1991, Blood.

[136]  L. VázquezSell,et al.  Graft-versus-host disease. , 1991, The New England journal of medicine.

[137]  G. Janossy,et al.  Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. , 1991, Bone marrow transplantation.

[138]  G. Gahrton,et al.  Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. , 1991, Bone marrow transplantation.

[139]  W. Wilmanns,et al.  Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients , 1990 .

[140]  A. Fischer,et al.  SPECIFIC ELIMINATION OF ALLOREACTIVE T CELLS BY AN ANTI‐INTERLEUKIN-2 RECEPTOR B CHAIN‐SPECIFIC IMMUNOTOXIN , 1990, Transplantation.

[141]  O. Ringdén,et al.  A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors--acute graft-versus-host disease, and splenectomy. , 1990, Transplantation.

[142]  H. Prentice,et al.  A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. , 1990, Bone marrow transplantation.

[143]  J. Bergerat,et al.  Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) , 1990, Blood.

[144]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[145]  J. Gabert,et al.  DETECTION OF RESIDUAL bcr/abl TRANSLOCATION BY POLYMERASE CHAIN REACTION IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER BONE-MARROW TRANSPLANTATION , 1989, The Lancet.

[146]  H. Deeg,et al.  Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. , 1989, The New England journal of medicine.

[147]  James,et al.  Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. , 1989, Blood.

[148]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[149]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[150]  G. Morgan,et al.  POLYMERASE CHAIN REACTION FOR DETECTION OF RESIDUAL LEUKAEMIA , 1989, The Lancet.

[151]  D. Smeets,et al.  Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. , 1989, Blood.

[152]  M. Horowitz,et al.  Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. , 1989, Transplantation proceedings.

[153]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[154]  R. Hoffmann,et al.  Risk factors for acute graft‐versus‐host disease , 1987, British journal of haematology.

[155]  H. Deeg,et al.  Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  A. Gratwohl,et al.  European experience of bone marrow transplantation for leukemia. , 1987, Transplantation proceedings.

[157]  G. Gahrton,et al.  A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. , 1986, Bone marrow transplantation.

[158]  R. Renkonen,et al.  BONE MARROW TRANSPLANTATION IN THE RAT: B LYMPHOCYTE ACTIVATION IN ACUTE GRAFT‐VERSUS‐HOST DISEASE , 1986, Transplantation.

[159]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[160]  R. Storb,et al.  Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience , 1985, Immunological reviews.

[161]  G. Janossy,et al.  DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTS , 1984, The Lancet.

[162]  S. Slavin,et al.  Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. , 1984, Journal of immunology.

[163]  D. Sachs,et al.  Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts , 1984, Nature.

[164]  R. Storb,et al.  ASSOCIATION BETWEEN HLA-B ANTIGENS AND ACUTE GRAFT-VERSUS-HOST DISEASE , 1983, The Lancet.

[165]  H. Deeg,et al.  Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. , 1983, Annals of internal medicine.

[166]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[167]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[168]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[169]  K. Sullivan,et al.  Chronic cutaneous graft-versus-host disease in man. , 1978, The American journal of pathology.

[170]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[171]  M. Cheever,et al.  ADOPTIVE CHEMOIMMUNOTHERAPY OF CANCER IN ANIMALS: A REVIEW OF RESULTS, PRINCIPLES, AND PROBLEMS * , 1976, Annals of the New York Academy of Sciences.

[172]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[173]  B. Ringelhann,et al.  Letter: Pseudohyperkalaemia in acute myeloid leukaemia. , 1974, Lancet.

[174]  A. Friedenstein,et al.  OSTEOGENIC PRECURSOR CELLS OF BONE MARROW IN RADIATION CHIMERAS , 1971, Transplantation.

[175]  A. Friedenstein,et al.  Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.

[176]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[177]  H. C. Bumpus.  The Apparent Disappearance of Pulmonary Metastasis in a Case of Hypernephroma Following Nephrectomy1 , 1928 .

[178]  M. Remberger,et al.  Granulocyte colony-stimulating factor affects serum levels of soluble interleukin-2 receptors after allogeneic stem cell transplantation. , 2005, Haematologica.

[179]  T. Klingebiel,et al.  How and when should we monitor chimerism after allogeneic stem cell transplantation? , 2005, Bone Marrow Transplantation.

[180]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[181]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.

[182]  M. Remberger,et al.  The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[183]  P. Bartolomeo,et al.  Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia , 2000 .

[184]  S. Gerson,et al.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  J. Kaeda,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. , 2000, Blood.

[186]  M. Asaka,et al.  Possible role of granulocyte colony-stimulating factor in increased serum soluble interleukin-2 receptor-alpha levels after allogeneic bone marrow transplantation. , 1999, Leukemia & lymphoma.

[187]  F. Appelbaum.  Allogeneic marrow transplantation and the use of hematopoietic growth factors , 1995, Stem cells.

[188]  M. Zago,et al.  A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia , 1998 .

[189]  A. Caplan,et al.  Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. , 1992, Bone.

[190]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[191]  J. V. van Dongen,et al.  Detection of residual disease in acute leukemia using immunological markers. , 1988, Cancer treatment and research.

[192]  Olle Ringdén,et al.  The multifactorial etiology of graft-versus-host disease. , 1987, Immunology today.

[193]  D. H. Mellor,et al.  Real time , 1981 .